Latest Capital Raising News

Elanor Commercial Property Fund reported a $5.4 million statutory loss for FY25 despite a slight increase in Funds from Operations, while navigating a strategic capital raise and an unsolicited takeover offer from the Lederer Group.

QX Resources has acquired 100% of the Madaba Uranium Project in Tanzania, a site with promising historical uranium grades, and is raising $2.3 million to advance exploration and development.

High-Tech Metals Limited has successfully completed the placement of the shortfall from its recent entitlement issue, raising approximately $1 million before costs through new shares and listed options.

Decidr AI Industries has locked in a $3.9 million underwriting agreement with Morgans Corporate Limited to back the exercise of listed options expiring this month, providing crucial funding ahead of its DecidrOS Beta release.

Victory Metals secures $11.5 million through a strategic placement to accelerate drilling and development at its North Stanmore heavy rare earth project, reinforcing its position as Australia’s leading rare earths explorer.

Calix Limited reported solid FY25 results with 17% growth in product revenue, a 23% cut in operating costs, and an extended 18-month cash runway, while progressing key decarbonisation projects.

Imugene Limited reported a significant 54% reduction in net loss for FY25, driven by cost efficiencies and promising clinical progress in its immuno-oncology pipeline. The company’s lead asset, azer-cel, achieved a 79% response rate in Phase 1b trials and secured FDA Fast Track designation.

Peninsula Energy Limited has had its ASX trading suspension lifted following the completion of a placement and institutional entitlement offer, signaling renewed market activity.

Peninsula Energy has successfully completed the first tranche of a fully underwritten A$69.9 million equity raise, securing strong institutional support including cornerstone investors Tees River and Davidson Kempner. The company now opens its retail entitlement offer to shareholders, aiming to fund the ramp-up of uranium production at its Lance Project in Wyoming.

Amplia Therapeutics has successfully raised A$2.65 million through its Share Purchase Plan, exceeding expectations and bolstering funding for pivotal clinical trials of its lead drug narmafotinib.

Propel Funeral Partners reported a 7.9% revenue increase in FY25, driven by acquisitions and modest organic growth, while maintaining strong cash flow and a solid balance sheet. The company signals continued expansion supported by favorable demographics and a leadership transition.

Bio-Gene Technology Limited reported a net loss of AUD 2.58 million for FY2025 while making significant strides in developing its bio-insecticides Flavocide and Qcide, securing US Department of Defense grants and expanding global partnerships.